Future Science OA (Aug 2021)
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy
- Matteo Ferro,
- Dragoş-Florin Babă,
- Ottavio de Cobelli,
- Gennaro Musi,
- Giuseppe Lucarelli,
- Daniela Terracciano,
- Angelo Porreca,
- Gian Maria Busetto,
- Francesco Del Giudice,
- Francesco Soria,
- Paolo Gontero,
- Francesco Cantiello,
- Rocco Damiano,
- Papalia Rocco,
- Roberto Mario Scarpa,
- Abdal Rahman Abu Farhan,
- Riccardo Autorino,
- Antonio Brescia,
- Michele Marchioni,
- Andrea Mari,
- Andrea Minervini,
- Nicola Longo,
- Francesco Chiancone,
- Sisto Perdona’,
- Biagio Barone,
- Pietro De Placido,
- Michele Catellani,
- Danilo Bottero,
- Pasquale Ditonno,
- Michele Battaglia,
- Stefania Zamboni,
- Alessandro Antonelli,
- Francesco Greco,
- Giorgio Ivan Russo,
- Salvatore Smelzo,
- Rodolfo Hurle,
- Nicolae Crisan,
- Matteo Manfredi,
- Francesco Porpiglia,
- Felice Crocetto,
- Carlo Buonerba,
- Alina Danilesco,
- Mihai Dorin Vartolomei
Affiliations
- Matteo Ferro
- 1Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy
- Dragoş-Florin Babă
- 2Department of Cell & Molecular Biology, University of Medicine and Pharmacy, Targu Mures, Romania
- Ottavio de Cobelli
- 1Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy
- Gennaro Musi
- 1Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy
- Giuseppe Lucarelli
- 4Department of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy
- Daniela Terracciano
- 5Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
- Angelo Porreca
- 6Department of Oncological Urology, Veneto Institute of Oncology IOV, IRCSS, Padua, Italy
- Gian Maria Busetto
- 7Department of Urology, ‘Sapienza’ University of Rome, Policlinico Umberto I Hospital, Rome, Italy
- Francesco Del Giudice
- 7Department of Urology, ‘Sapienza’ University of Rome, Policlinico Umberto I Hospital, Rome, Italy
- Francesco Soria
- 8Division of Urology, Department of Surgical Sciences, AOU Citta´ della Salute e della Scienza, Turin School of Medicine, Turin, Italy
- Paolo Gontero
- 8Division of Urology, Department of Surgical Sciences, AOU Citta´ della Salute e della Scienza, Turin School of Medicine, Turin, Italy
- Francesco Cantiello
- 9Department of Urology, University of Catanzaro, Università ‘Magna Græcia’, Catanzaro, Italy
- Rocco Damiano
- 9Department of Urology, University of Catanzaro, Università ‘Magna Græcia’, Catanzaro, Italy
- Papalia Rocco
- 10Department of Urology, Policlinic University Campus of Bio-Medicine of Rome, Rome, Italy
- Roberto Mario Scarpa
- 10Department of Urology, Policlinic University Campus of Bio-Medicine of Rome, Rome, Italy
- Abdal Rahman Abu Farhan
- 9Department of Urology, University of Catanzaro, Università ‘Magna Græcia’, Catanzaro, Italy
- Riccardo Autorino
- 11Division of Urology, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
- Antonio Brescia
- 1Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy
- Michele Marchioni
- 12Department of Medical, Oral & Biotechnological Sciences, Gabriele d'Annunzio University of Chieti & Pescara, Chieti, Italy
- Andrea Mari
- 13Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy
- Andrea Minervini
- 13Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy
- Nicola Longo
- 14Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy
- Francesco Chiancone
- 15Urology Unit, AORN Cardarelli, Naples, Italy
- Sisto Perdona’
- 16Division of Urology, National Cancer Institute IRCCS Pascale Foundation, Naples, Italy
- Biagio Barone
- 14Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy
- Pietro De Placido
- 17Department of Clinical Medicine & Surgery, University of Naples Federico II, Naples, Italy
- Michele Catellani
- 1Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy
- Danilo Bottero
- 1Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy
- Pasquale Ditonno
- 4Department of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy
- Michele Battaglia
- 4Department of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy
- Stefania Zamboni
- 18Department of Urology, ASST Spedali Civili di Brescia, Brescia, Italy
- Alessandro Antonelli
- 18Department of Urology, ASST Spedali Civili di Brescia, Brescia, Italy
- Francesco Greco
- 20Clinic of Urology, Centro Salute Uomo, Bergamo, Italy
- Giorgio Ivan Russo
- 21Department of Urology, University of Catania, Catania, Italy
- Salvatore Smelzo
- 22Department of Urology, San Raffaele Turro Hospital, San Raffaele University, Milan, Italy
- Rodolfo Hurle
- 23Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Nicolae Crisan
- 24Department of Urology, University of Medicine & Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania
- Matteo Manfredi
- 25Urology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy
- Francesco Porpiglia
- 25Urology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy
- Felice Crocetto
- 14Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy
- Carlo Buonerba
- 26Department of Oncology & Hematology, Regional Reference Center for Rare Tumors, University of Naples Federico II, Naples, Italy
- Alina Danilesco
- 2Department of Cell & Molecular Biology, University of Medicine and Pharmacy, Targu Mures, Romania
- Mihai Dorin Vartolomei
- 1Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy
- DOI
- https://doi.org/10.2144/fsoa-2021-0008
- Journal volume & issue
-
Vol. 7,
no. 7
Abstract
Aim: To investigate the prognostic role of neutrophil percentage-to-albumin ratio (NPAR) in muscle-invasive bladder cancer (MIBC) patients treated with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Patients & methods: 213 patients were included. Inclusion criteria: Nonmetastatic, MIBC (cT2-T4aN0M0), at least three cycles of NAC, undergone RC and with blood count within 30 days before NAC. Results: Five-years overall survival (OS) with NPAR >18 was 34.06% (95% CI: 18.3–50.5) and 65.37% (95% CI: 52.4–75.6) with NPAR 18 was 42.9% (95% CI: 23.9–60.7) and 74.5% (95% CI: 62.6–83.1) with NPAR <18 (p < 0.001). In multivariable analysis, NPAR increased OS of 1.3 points and CSS of 4.37 points. Conclusion: High NPAR prior to NAC seems to be a strong predictor of OS and CSS in MIBC patients treated with NAC and RC.
Keywords
- bladder cancer
- neoadjuvant chemotherapy
- neutrophil percentage-to-albumin ratio
- neutrophil-to-lymphocyte ratio
- survival
